Teva Parkinson's Agent Azilect Will Launch Within 10 Weeks
Partner Eisai will continue to co-develop the MAO-B inhibitor for Alzheimer's disease, but it is "still considering" whether it will opt to co-promote the agent for Parkinson's.
Partner Eisai will continue to co-develop the MAO-B inhibitor for Alzheimer's disease, but it is "still considering" whether it will opt to co-promote the agent for Parkinson's.